At present, DSIP remains an experimental peptide with limited high-quality human data, and it has not been approved as a standard treatment for insomnia or psychiatric conditions
In an exploratory analysis of the results of the REWIND trial, a CVOT for dulaglutide (another once-weekly GLP-1RA), a highly significant reduction of 13%-14% was observed in the risk of substantive cognitive impairment, also after adjustment for baseline scores, age ,sex, ethnic origin or education [26]
New eating habits emerged, ranging from the widespread diffusion of the western-style diet, especially among younger individuals and low-income classes, on the one hand, to the rise of plant-based diets on the opposite [3,4,5,6,7]